November 15, 2012 (Vol. 32, No. 20)

Durata Therapeutics hired Allison Wey as vp of investor relations and public affairs. Before joining Durata, Wey served as vp, investor relations and corporate affairs of Par Pharmaceuticals. She also served as vp, investor relations and corporate communications at Boron, LePore, and Associates.

Allison Wey

Rapid Pathogen Screening appointed Caroline Popper, M.D., and Hanjoon Ryu to its board of directors…Synthetic Biologics named Charles B. Shoemaker, Ph.D., to its scientific advisory board…Nabsys added Peter Lewis as CFO and Darren Lee as vp, business development…Advanced Clinical hired Susan Seroskie as evp, strategic resourcing.

Sirona Biochem named Neil Belenkie as CEO. Belenkie is the founder of GrowthPoint Group. Previously, he co-founded RevGen and was a consultant at Odgers Berndston. Additional experience includes leadership roles at Ortho Biotech and Hoffmann-La Roche.

Neil Belenkie

Richard Flavell, Ph.D., is now chief scientific advisor at Ceres…Silence Therapeutics added Tim Freeborn as its finance director…Corcept Therapeutics appointed Daniel M. Bradbury to its board of directors…Genome Canada named Lorne Hepworth chair of its board of directors…Henry Lenz, Ph.D., joined TNI BioTech as quality control officer.

Dyax appointed Marc Kozin to its board of directors. Kozin was North American president of L.E.K. Consulting. He also serves on the boards of Endocyte, Medical Simulation, UFP Technologies, CrunchTime! Information Systems, and DukeEngage.

Marc Kozin

Rosetta Genomics added E. Robert Wassman, M.D., as CMO and Dganit Bar, Ph.D., as CSO…Zyngenia appointed Jason Rhodes to its board of directors…Christian Weyer is now president and CEO at Fate Therapeutics…Rheonix appointed Bill Colston, Ph.D., to its board of directors…Cerecor hired James Vornov, M.D. Ph.D., as svp, clinical development and regulatory affairs and John Kaiser as vp of commercialization and business development.

Cynthia Patton is now svp and chief compliance officer at Amgen. Patton joined Amgen in 2005, and was most recently vp in the law department. Previously, she served as the lead commercial lawyer for the oncology and inflammation business units.

Cynthia Patton

Sequenom added Bill Bowen as svp and general counsel…LabCorp appointed Peter M. Neupert to its board of directors…Vital Connect named Neal White, M.D., to its medical advisory board…NanoBio promoted David Peralta to CEO…Oramed Pharmaceuticals appointed Gerald Ostrov to its board of directors…Jeffrey Nieman joined Cymetrix as svp, remote operations…Sirona Biochem added Nigel Terrett as strategic advisor.

Richard J. Rubino joined Aerie Pharmaceuticals as CFO. Prior to joining Aerie, Rubino was CFO and chief accounting officer at Medco. He also served in accounting and business alliance positions at IBM and was a senior auditor at Price Waterhouse and Co.

Richard J. Rubino

MYOS hired Andrew J. Einhorn as CFO…Jonathan Turner, Ph.D., is now managing director and CEO of caprotec bioanalytics…LifeMap Sciences appointed Louis E. Silverman to its board of directors…NovAliX hired Luc Van Hijfte, Ph.D., as CSO drug discovery…Sanford-Burnham named Dwight A. Towler, M.D., Ph.D., director of its cardiovascular pathobiology program.

Cytos Biotechnology added Christian Itin, Ph.D., as CEO. Formerly, Dr. Itin was president and CEO of Micromet. Prior to joining Micromet, he co-founded Zyomyx. He is also on the board of directors at Zyngenia.

Christian Itin, Ph.D.

CSR Pharma Services appointed Michael Dubois, Eric Sheinen, Ph.D., and Wendy Stephenson, M.D., to its scientific and FDA board and Caroline Wang and Phoebe Yeh to its board of directors…Omeros added Cathy Melfi, Ph.D., as vp of regulatory affairs and quality systems and Albert Yu, M.D., as vp of clinical development…Amarantus BioSciences appointed Clinton O. Allen to its advisory board.

Send your People Announcements to [email protected]

Previous articleA First: Genome Sequencing Controls MRSA Outbreak
Next articleJanssen Launches Clinical Trials Database